Objective: Based on the theory of "cultivating soil and generating gold", the clinical efficacy of Liujunzi Decoction in treating copd at different weeks was investigated. Methods: A total of 90 patients with COPD with Lung-spleen qi deficiency treated in Jingdezhen Traditional Chinese Medicine Hospital from January 2020 to January 2022 were randomly divided into western medicine group, Chinese medicine group A and Chinese medicine group B, with 30 cases in each group.?The clinical efficacy, respiratory function index, immune index，Nutrition indicators and inflammatory index levels of the three groups were compared before and after intervention. Results: After treatment, the effective rates of western medicine group, Chinese medicine A group and Chinese medicine B group were 78.57%, 86.21% and 96.67%, respectively, and the levels of [ 第一作者：黄明儒，医学硕士，中医师，2581912372@qq.com 电话：18720928851 通讯作者：江久，医学学士，副主任中医师，917869664@qq.com 电话：18979866518 课题基金：江西省卫生健康委（2018A186） ]FEV1%,FEV1/FVC,FEF25% and FEF50% were improved (P<0.05), the levels of TNF-α,IL-6 and IL-33 were decreased (P<0.05); The above indexes in Chinese medicine group (group A, group B) were significantly higher than those in Western medicine group (P<0.05), and group B was more significant than group A (P<0.05). There were no significant differences in IgG, IgA IgM, Body weight, albumin and transferrin before and after treatment in western medicine group (P>0.05). After treatment, the levels of IgG, IgA， IgM ，Body weight, albumin and transferrin in Chinese medicine?group (group A and B) were statistically different, and group B was more significant than group A (P<0.05). Conclusion: Modified Liujunzi Decoction has significant clinical efficacy in the treatment of COPD, which mainly improves the quality of life of COPD patients by improving the body's immunity, thereby reducing the level of inflammation, alleviating the inflammatory response, improving the respiratory function of small airway, and the longer the week, the more significant the efficacy.